This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.
| AOD-9604 | Enicepatide (CT-388) | |
|---|---|---|
| Highest evidence tier on the page | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. |
| Regulatory status | Not approved for human use | Not stated |
| Research area | Metabolic and incretin | Metabolic and incretin |
| Regulator-approved dose on file | No approved dose | No approved dose |
| Molecular formula | C78H123N23O23S2 | C226H345FN48O67, per a peer-reviewed phase 1 publication. |
| Molar mass | 1815.1 g/mol for the disulfide-cyclised form. The reduced linear form is about 1817.1, which vendor certificates sometimes quote instead. | Approximately 4,825 Da, per the same publication; a commercial vendor lists 4,825.44 Da, consistent within rounding. |
| CAS number | 221231-10-3 | Not reliably established; two secondary sources conflict (2919675-94-6 vs. 2869147-44-2) with no primary registry confirmation of either. |
| Registered trials on this site | 3 in the tracker | 6 in the tracker |
| Furthest registered phase | Phase 2 | Phase 3 |
| Trials currently active | 0 | 4 |
| Trial sponsors | Lateral Pharma Pty Ltd | Hoffmann-La Roche, Carmot Therapeutics, Inc. |
| Published trials covered on its page | 7 | Not stated |
| Amounts studied in those trials | METAOD001: 25 to 400 micrograms per kilogram, single intravenous doses for Single doses with a 7 day washout METAOD002: 25, 50 and 100 micrograms per kilogram, single intravenous doses for Single doses with a 7 day washout METAOD004: 9, 27 or 54 mg once daily, oral for 7 days As reported on the compound page. Amounts are not comparable between compounds. | Not stated |
| What is not known | Whether it causes fat loss in a human being at any dose by any route. The 12 week study produced a signal at its lowest dose, the 24 week confirmatory study found no significant difference against placebo, and no third study was ever run. The... | The low- and middle-dose results from both phase 2 trials remain unreported in any source checked; only the top, 24 mg, dose's results have been disclosed publicly. The exact phase 3 dosing regimen has not been disclosed. The 24-week phase 1 extension cohort's exact dose... |
Full pages: AOD-9604 and Enicepatide (CT-388). See also the clinical trial tracker and how we grade evidence.
Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.
